Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Intrinsic Value
The intrinsic value of one GLUE stock under the Base Case scenario is 7.69 USD. Compared to the current market price of 4.18 USD, Monte Rosa Therapeutics Inc is Undervalued by 46%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Monte Rosa Therapeutics Inc
Fundamental Analysis

Revenue & Expenses Breakdown
Monte Rosa Therapeutics Inc
Balance Sheet Decomposition
Monte Rosa Therapeutics Inc
Current Assets | 332.3m |
Cash & Short-Term Investments | 326.1m |
Receivables | 1.4m |
Other Current Assets | 4.8m |
Non-Current Assets | 60.9m |
PP&E | 55.6m |
Other Non-Current Assets | 5.3m |
Free Cash Flow Analysis
Monte Rosa Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Monte Rosa Therapeutics Inc
Revenue
|
159.5m
USD
|
Operating Expenses
|
-161.6m
USD
|
Operating Income
|
-2.1m
USD
|
Other Expenses
|
8.3m
USD
|
Net Income
|
6.2m
USD
|
GLUE Profitability Score
Profitability Due Diligence
Monte Rosa Therapeutics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Monte Rosa Therapeutics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
GLUE Solvency Score
Solvency Due Diligence
Monte Rosa Therapeutics Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
Monte Rosa Therapeutics Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GLUE Price Targets Summary
Monte Rosa Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for GLUE is 16.49 USD with a low forecast of 10.1 USD and a high forecast of 21 USD.
Dividends
Current shareholder yield for GLUE is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one GLUE stock under the Base Case scenario is 7.69 USD.
Compared to the current market price of 4.18 USD, Monte Rosa Therapeutics Inc is Undervalued by 46%.